| Margins | Expected margin uplift via new launches and cost optimization. |
|---|---|
| Demand visibility | Strong; demands runs on legacy prescriber loyalty. |
| Management confidence | High; leveraging ChrysCapital's healthcare expertise. |
Growth
Revenue MAT July '26 down 8% for core brand Minipress XL; FY23-26 Revenue CAGR was -2% and PAT CAGR was -3%.
Outlook
Targeting above-market growth via 900+ member field force. Acquiring Minipress XL brand rights for INR 1,250 Cr and in-licensing retina portfolio.
Risks
One-time transition costs in Q2-Q4 FY27 including partnership termination fees and sales returns; temporary margin pressure during field-force expansion.
Earnings Call Transcript filed with BSE, NSE: NOVARTIND. Summary written with AI assistance from the document.
Novartis India Ltd: key numbers
- Share price
- ₹1,961.40
- Market cap
- ₹4,843 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- 49.5×Sector 50.4×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 0.15%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Novartis India Annual General Meeting
Novartis India issued a corrigendum to its 78th AGM notice. This correction clarifies ESOP 2026 scheme details and the company's nature of industry.
Novartis India Investor Presentation: Key Takeaways
Novartis India Limited (NIL) shifts to a direct-to-market model under new ownership by ChrysCapital, acquiring the 'Minipress' brand for ₹1,250 Cr and in-licensing an ophthalmic portfolio.
Novartis India Other Announcement
Novartis India dispatched physical letters with the FY25-26 Annual Report web-link to non-email shareholders per Reg 36(1)(b). This is a routine compliance communication with no financial or business impact.
Novartis India Partnership
Novartis India signed an exclusive distribution deal with Novartis Healthcare for its retina portfolio in India. Upfront consideration of INR 10 Crore expands NIL's ophthalmology presence.
- Value
- ₹10.00 Cr
Novartis India Business Update
Novartis India acquired trademarks 'Minipress' and 'Minipres' from Pfizer for ₹1,250.001 Crore. The IP acquisition strengthens its hypertension and BPH portfolio in India.
- Value
- ₹1,250 Cr
Novartis India Acquisition Worth ₹1,250 Cr
Novartis India acquired Minipress/Minipres trademarks and related IP from Pfizer for ₹1,250 Crore. The board approved and the asset purchase agreement was executed on September 7, 2026.
- Value
- ₹1,250 Cr